222. 一次性ネフローゼ症候群 Primary nephrotic syndrome Clinical trials / Disease details
臨床試験数 : 285 / 薬物数 : 285 - (DrugBank : 108) / 標的遺伝子数 : 62 - 標的パスウェイ数 : 191
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04424862 (ClinicalTrials.gov) | June 9, 2020 | 7/6/2020 | Multitarget Therapy for Idiopathic Membranous Nephropathy | Multitarget Therapy for Idiopathic Membranous Nephropathy | Efficacy | Drug: Prednisone, ciclosporin and mycophenolate mofetil;Drug: Ponticelli Regimen | Beijing Friendship Hospital | NULL | Completed | 18 Years | 70 Years | All | 82 | Phase 4 | China |
| 2 | JPRN-UMIN000001099 | 2007/10/01 | 31/03/2008 | Optimal use of ciclosporin in idiopathic membranous nephropathy associated with nephrotic syndrome | idiopathic membranous nephropathy associated with nephrotic syndrome | Steroid group: Immunosuppressive therapy is started by predonisolone 0.8mg/kg/day (max 60mg/day). The dose is decreased by 5mg/day in 2 to 4 weeks after remission. The cases who do not reach remission for 4 weeks, predonisolone is decreased to 0.6mg/kg/day, and ciclosporin (2mg/kg/day) is started once a day. Serum concentration of ciclosporin is measured 2hr after administration, and the dose is adjusted. (The target serum concentration is 800-1000ng/mL.) Steroid + ciclosporin group: Immunosupressive therapy is started by predonisolone 0.6mg/kg/day and ciclosporin 2mg/kg/day (once a day). Serum concentration of ciclosporin is measured 2hr after administration, and the dose is adjusted. (The target serum concentration is 800-1000ng/mL.) The dose of predonisolone is decreased by 5mg/day in 2 to 4 weeks after remission. Ciclosporin is continued after remission. (The target C2 is 600-800 ng/mL.) The cases who do not reach remission after 4 weeks, predonisolone is decreased by 5mg/4-8week, and ciclosporin is continued for 6 months. The target C2 is 800-1000ng/mL. At 6 months after, the therapy of non-respnder is not restricted. | Division of Kidney and Dialysis, Department of Internal Medicine,Hyogo College of Medicine | NULL | 16years-old | Not applicable | Male and Female | 50 | Phase 4 | Japan |